Shots:

• The EMA’s CHMP has recommended marketing authorization of Amsparity- a biosimilar referencing AbbVie’s Humira
• Amsparity will be available in a 40 mg pre-filled syringe and pre-filled pen for adults and a 20 mg pre-filled syringe and 40 mg/0.8 mL vial for children. Amsparity showed high bio-similarity data in terms of quality- safety and efficacy to Humira
• Amsparity is mAb targeting TNFα- act by blocking its interaction with the p55 and p75 cell-surface TNF receptors and is indicated for multiple autoimmune disorders including RA- AS- CD

Click here to­ read full press release/ article | Ref: EMA | Image: STAT